GRAIL, Inc.

NASDAQ:GRAL

Medical - Diagnostics & Research

Healthcare
$102.10 +3.20%

+$1.90 today

Market cap
$4.59B
Beta
3.16
P/E (TTM)
-6.3
EPS (TTM)
-$9.73
52W Low $29.95High $118.84

Volume 0.62M

Average 0.77M

GRAL Net Income

Bottom-line profit, the starting point for calculating cash from operations.

GRAIL, Inc.NASDAQ: GRAL

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of $110.25M (cash outflow) fell 3.3% year over year, ahead of the -11.6% change in trailing-twelve-month net income. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at -57.7% a year.

Context

  • Net income amounted to 277.5% of revenue in FY2025, down 1336.5 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$352.14M (-13.8%) for the fiscal year ending Dec 2026, a step up from the -79.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$110.25M+18.3% QoQ
Last fiscal yearDec 2025
-$408.35M-79.9% YoY
LTMJun 2026
-$391.59M-11.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.3%+34.3%+37.6 pp
1 year-79.9%-13.8%+66.1 pp
3-year CAGR-57.7%-4.0%+53.7 pp
5-year CAGR-5.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(408.35M) USD
Year-over-year change
+79.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GRAL compares with its peers on the latest reported figures

  • GRAL's LTM Jun 2026 net income of $391.59M is the 3rd largest of the 10 companies compared; the peer median is $95.55M.
  • Its year-over-year change of -11.6% is the 6th highest of 9, against a peer median of +17.6%.
  • Net income amounts to 236.9% of revenue for GRAL, versus a peer median of 23.3%.
GRAL Competitors Peer median
Net Income for GRAL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$485.07M +21.6%-14.0%37.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$399.9M +294.4%+48.4%48.2%
GRALGRAIL, Inc.LTM Jun 2026$391.59M -11.6%-57.7%236.9%
NTRANatera, Inc.LTM Jun 2026$192.35M -24.0%-27.6%7.1%
WGSGeneDx Holdings Corp.LTM Jun 2026$106.36M -7664.5%-66.3%23.4%
PSNLPersonalis, Inc.LTM Mar 2026$95.55M +13.7%-10.5%148.1%
FLGTFulgent Genetics, Inc.LTM Mar 2026$74.56M +78.1%—23.3%
NEONeoGenomics, Inc.LTM Jun 2026$51.88M -50.1%-9.2%6.8%
BLLNBillionToOne, Inc.LTM Jun 2026$37.71M ——9.5%
CSTLCastle Biosciences, Inc.LTM Mar 2026$12.83M +153.1%-28.9%3.8%
Peer median (excluding GRAL) $95.55M+17.6%-14.0%23.3%

Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.25B)(5.4B)(1.47B)(2.03B)(408.35M)
Depreciation & Amortization58.45M154.76M158.7M158.06M156.34M
Deferred Income Tax0(39.06M)(38.15M)(134.25M)(126.15M)
Stock-Based Compensation681.91M75.73M97.24M86.08M58.28M
Change in Working Capital21.59M(14.46M)7.72M(24.28M)12.41M
Accounts Receivables(6.88M)(8.68M)(1.38M)(3.37M)1.69M
Inventory(5.67M)(14.08M)(1.94M)3.07M2.62M
Accounts Payables1.3M2.34M2.89M(14.64M)(2.73M)
Other Working Capital32.85M5.95M8.16M(9.35M)10.84M
Other Non-Cash Items(201M)4.66B644.39M1.36B8.46M
Operating Cash Flow(688.13M)(561.31M)(595.8M)(577.16M)(299.01M)
Capital Expenditures(69.93M)(22.86M)(12.89M)(5.21M)(909K)
Acquisitions (Net)00000
Purchases of Investments000(545.8M)(1.31B)
Sales of Investments00001.22B
Other Investing Activities414.74M0000
Investing Cash Flow344.81M(22.86M)(12.89M)(551.01M)(85.05M)
Debt Repayment00000
Common Stock Issued5.98M000423.32M
Common Stock Repurchased(170K)0000
Dividends Paid00000
Other Financing Activities388.93M604.82M463.77M1.24B0
Financing Cash Flow394.74M604.82M463.77M1.24B423.32M
Effect of Forex Changes(194.61M)(511K)305K(62K)(147K)
Net Change in Cash(143.19M)20.13M(144.62M)116.07M39.12M
Free Cash Flow(758.06M)(584.17M)(608.69M)(582.36M)(299.01M)

GRAIL, Inc.

NASDAQ:GRAL

Intrinsic Alpha fair value

Locked

Current Price

$102.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.